Disruption of an hTERT-mTOR-RAPTOR protein complex by a phytochemical perillyl alcohol and rapamycin

Molecular and Cellular Biochemistry

Volumn 375, Issue 1-2, 2013, Pages 97-104

  Sundin, Tabetha ^a   Peffley, Dennis M ^a   Hentosh, Patricia ^a  

^a OLD DOMINION UNIVERSITY   (United States)

Author keywords

hTERT mTOR RAPTOR complex; Perillyl alcohol; Post translational regulation; Rapamycin; Telomerase activity

Indexed keywords

HEAT SHOCK PROTEIN 90; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MESSENGER RNA; PERILLYL ALCOHOL; PROTEIN; PROTEIN KINASE B; RAPAMYCIN; REGULATORY ASSOCIATED PROTEIN OF MTOR; S6 KINASE; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME POLYMORPHISM; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; LYMPHOCYTE ACTIVATION; MALE; NATURAL KILLER CELL; PHYTOCHEMISTRY; PROSTATE CANCER; WESTERN BLOTTING;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE; DOWN-REGULATION; HSP90 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOPRECIPITATION; MONOTERPENES; MULTIPROTEIN COMPLEXES; PROTEIN BINDING; RIBOSOMAL PROTEIN S6 KINASES; SIROLIMUS; TELOMERASE; TOR SERINE-THREONINE KINASES;

EID: 84873056486     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-012-1532-3     Document Type: Article

References (45)

1. Sabatini DM, Erdjument-Bromage H, Lui M, Tempst P, Snyder SH (1994) RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell 78:35-43
2. Hara K, Maruki Y, Long X, Yoshino K, Oshiro N, Hidayat S, Tokunaga C, Avruch J, Yonezawa K (2002) Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 110:177-189
3. Nojima H, Tokunaga C, Eguchi S, Oshiro N, Hidayat S, Yoshino K, Hara K, Tanaka N, Avruch J, Yonezawa K (2003) The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif. J Biol Chem 278:15461-15464
4. Oshiro N, Yoshino K, Hidayat S, Tokunaga C, Hara K, Eguchi S, Avruch J, Yonezawa K (2004) Dissociation of raptor from mTOR is a mechanism of rapamycin-induced inhibition of mTOR function. Genes Cells 9:359-366
5. Yip CK, Murata K, Walz T, Sabatini DM, Kang SA (2010) Structure of the human mTOR complex I and its implications for rapamycin inhibition. Mol Cell 38:768-774
6. Delgoffe GM, Kole TP, Cotter RJ, Powell JD (2009) Enhanced interaction between Hsp90 and raptor regulates mTOR signaling upon T cell activation. Mol Immunol 46:2694-2698
7. Ohji G, Hidayat S, Nakashima A, Tokunaga C, Oshiro N, Yoshino K, Yokono K, Kikkawa U, Yonezawa K (2006) Suppression of the mTOR-raptor signaling pathway by the inhibitor of heat shock protein 90 geldanamycin. J Biochem 139:129-135
8. Forsythe HL, Jarvis JL, Turner JW, Elmore LW, Holt SE (2001) Stable association of hsp90 and p23, but Not hsp70, with active human telomerase. J Biol Chem 276:15571-15574
9. Vaziri H, Benchimol S (1998) Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span. Curr Biol 8:279-282
10. Cong YS, Wright WE, Shay JW (2002) Human telomerase and its regulation. Microbiol Mol Biol Rev 66:407-425
11. Blackburn EH (2000) The end of the (DNA) line. Nat Struct Biol 7:847-850
12. Greider CW, Blackburn EH (1987) The telomere terminal transferase of tetrahymena is a ribonucleoprotein enzyme with two kinds of primer specificity. Cell 51:887-898
13. Kawauchi K, Ihjima K, Yamada O (2005) IL-2 increases human telomerase reverse transcriptase activity transcriptionally and posttranslationally through phosphatidylinositol 3′-kinase/Akt, heat shock protein 90, and mammalian target of rapamycin in transformed NK cells. J Immunol 174:5261-5269
14. Sundin T, Peffley DM, Gauthier D, Hentosh P (2012) The isoprenoid perillyl alcohol inhibits telomerase activity in prostate cancer cells. Biochimie 94:2639-2648
15. Peffley DM, Sharma C, Hentosh P, Buechler RD (2007) Perillyl alcohol and genistein differentially regulate PKB/Akt and 4E-BP1 phosphorylation as well as eIF4E/eIF4G interactions in human tumor cells. Arch Biochem Biophys 465:266-273
16. Chaudhary SC, Alam MS, Siddiqui MS, Athar M (2009) Perillyl alcohol attenuates Ras-ERK signaling to inhibit murine skin inflammation and tumorigenesis. Chem Biol Interact 179:145-153
17. Cho HY, Wang W, Jhaveri N, Torres S, Tseng J, Leong MN, Lee DJ, Goldkorn A, Xu T, Petasis NA, Louie SG, Schonthal AH, Hofman FM, Chen TC (2012) Perillyl alcohol for the treatment of temozolomide-resistant gliomas. Mol Cancer Ther 11:2462-2472
18. Farazuddin M, Sharma B, Khan AA, Joshi B, Owais M (2012) Anticancer efficacy of perillyl alcohol-bearing PLGA microparticles. Int J Nanomedicine 7:35-47
19. Lebedeva IV, Su ZZ, Vozhilla N, Chatman L, Sarkar D, Dent P, Athar M, Fisher PB (2008) Chemoprevention by perillyl alcohol coupled with viral gene therapy reduces pancreatic cancer pathogenesis. Mol Cancer Ther 7:2042-2050
20. Mo H, Elson CE (2004) Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention. Exp Biol Med (Maywood) 229:567-585
21. da Fonseca CO, Schwartsmann G, Fischer J, Nagel J, Futuro D, Quirico-Santos T, Gattass CR (2008) Preliminary results from a phase I/II study of perillyl alcohol intranasal administration in adults with recurrent malignant gliomas. Surg Neurol 70:259-266; discussion 266-7
22. da Fonseca CO, Simao M, Lins IR, Caetano RO, Futuro D, Quirico-Santos T (2011) Efficacy of monoterpene perillyl alcohol upon survival rate of patients with recurrent glioblastoma. J Cancer Res Clin Oncol 137:287-293
23. Morgan-Meadows S, Dubey S, Gould M, Tutsch K, Marnocha R, Arzoomanin R, Alberti D, Binger K, Feierabend C, Volkman J, Ellingen S, Black S, Pomplun M, Wilding G, Bailey H (2003) Phase I trial of perillyl alcohol administered four times daily continuously. Cancer Chemother Pharmacol 52:361-366
24. Stratton SP, Alberts DS, Einspahr JG, Sagerman PM, Warneke JA, Curiel-Lewandrowski C, Myrdal PB, Karlage KL, Nickoloff BJ, Brooks C, Saboda K, Yozwiak ML, Krutzsch MF, Hu C, Lluria-Prevatt M, Dong Z, Bowden GT, Bartels PH (2010) A phase 2a study of topical perillyl alcohol cream for chemoprevention of skin cancer. Cancer Prev Res (Phila) 3:160-169
25. Jimeno A, Rudek MA, Kulesza P, Ma WW, Wheelhouse J, Howard A, Khan Y, Zhao M, Jacene H, Messersmith WA, Laheru D, Donehower RC, Garrett-Mayer E, Baker SD, Hidalgo M (2008) Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumors. J Clin Oncol 26:4172-4179
26. Buechler RD, Peffley DM (2004) Proto oncogene/eukaryotic translation initiation factor (eIF) 4E attenuates mevalonate-mediated regulation of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase synthesis. Mol Carcinog 41:39-53
27. Schalm SS, Fingar DC, Sabatini DM, Blenis J (2003) TOS motif-mediated raptor binding regulates 4E-BP1 multisite phosphorylation and function. Curr Biol 13:797-806
28. Sundin T, Hentosh P (2012) InTERTesting association between telomerase, mTOR and phytochemicals. Expert Rev Mol Med 14:e8
29. Ye L, Varamini B, Lamming DW, Sabatini DM, Baur JA (2012) Rapamycin has a biphasic effect on insulin sensitivity in C2C12 myotubes due to sequential disruption of mTORC1 and mTORC2. Front Genet 3:177
30. Beevers CS, Chen L, Liu L, Luo Y, Webster NJ, Huang S (2009) Curcumin disrupts the Mammalian target of rapamycin-raptor complex. Cancer Res 69:1000-1008
31. Kim JH, Park SM, Kang MR, Oh SY, Lee TH, Muller MT, Chung IK (2005) Ubiquitin ligase MKRN1 modulates telomere length homeostasis through a proteolysis of hTERT. Genes Dev 19:776-781
32. Cardenas ME, Cruz MC, Del Poeta M, Chung N, Perfect JR, Heitman J (1999) Antifungal activities of antineoplastic agents: Saccharomyces cerevisiae as a model system to study drug action. Clin Microbiol Rev 12:583-611
33. Galat A (2012) Functional diversity and pharmacological profiles of the FKBPs and their complexes with small natural ligands. Cell Mol Life Sci. doi: 10.1007/s00018-012-1206-z
34. Choi J, Chen J, Schreiber SL, Clardy J (1996) Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP. Science 273:239-242
35. Haendeler J, Hoffmann J, Rahman S, Zeiher AM, Dimmeler S (2003) Regulation of telomerase activity and anti-apoptotic function by protein-protein interaction and phosphorylation. FEBS Lett 536:180-186
36. Shiota M, Kusakabe H, Hikita Y, Nakao T, Izumi Y, Iwao H (2008) Pharmacogenomics of cardiovascular pharmacology: molecular network analysis in pleiotropic effects of statin - an experimental elucidation of the pharmacologic action from protein-protein interaction analysis. J Pharmacol Sci 107:15-19
37. Kang SS, Kwon T, Kwon DY, Do SI (1999) Akt protein kinase enhances human telomerase activity through phosphorylation of telomerase reverse transcriptase subunit. J Biol Chem 274:13085-13090
38. Sato S, Fujita N, Tsuruo T (2000) Modulation of Akt kinase activity by binding to Hsp90. Proc Natl Acad Sci USA 97:10832-10837
39. Holt SE, Aisner DL, Baur J, Tesmer VM, Dy M, Ouellette M, Trager JB, Morin GB, Toft DO, Shay JW, Wright WE, White MA (1999) Functional requirement of p23 and Hsp90 in telomerase complexes. Genes Dev 13:817-826
40. Chiu WT, Shen SC, Yang LY, Chow JM, Wu CY, Chen YC (2011) Inhibition of HSP90-dependent telomerase activity in amyloid beta-induced apoptosis of cerebral endothelial cells. J Cell Physiol 226:2041-2051
41. Makhnevych T, Houry WA (2011) The role of Hsp90 in protein complex assembly. Biochim Biophys Acta 1823:674-682
42. Majerska J, Sykorova E, Fajkus J (2011) Non-telomeric activities of telomerase. Mol Biosyst 7:1013-1023
43. Masutomi K, Possemato R, Wong JM, Currier JL, Tothova Z, Manola JB, Ganesan S, Lansdorp PM, Collins K, Hahn WC (2005) The telomerase reverse transcriptase regulates chromatin state and DNA damage responses. Proc Natl Acad Sci USA 102:8222-8227
44. Spagnolo L, Rivera-Calzada A, Pearl LH, Llorca O (2006) Three-dimensional structure of the human DNA-PKcs/Ku70/Ku80 complex assembled on DNA and its implications for DNA DSB repair. Mol Cell 22:511-519
45. Zhang MQ, Wilkinson B (2007) Drug discovery beyond the 'rule-of-five'. Curr Opin Biotechnol 18:478-488